权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

A new kinase inhibitor for glioblastoma

一种新的胶质母细胞瘤激酶抑制剂

基本信息

批准号：
10019480
负责人：
Raymond Daniel Blind
金额：
$ 18.49万
依托单位：
VANDERBILT UNIVERSITY MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-09-17 至 2022-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10019480
关键词：
1-Phosphatidylinositol 3-Kinase Agar Antineoplastic Agents Astrocytes Back Basic Science Binding Sites Brain Cancer Model Cell Culture Techniques Cell Line Cell Nucleus Cell model Cells Chemicals Chronic Clinical Trials Collaborations Complement Data Development Drug Design Drug Targeting Endocrine Endocrine System Diseases Engraftment Future G1/S Arrest Genome Glial Fibrillary Acidic Protein Glioblastoma Glioma Goals Grant Growth Human Industrialization Inositol Investments Knock-out Knockout Mice Letters Malignant Neoplasms Membrane Mus Mutation Nature Nuclear Oncogenic PTEN gene Paper Pathway interactions Pharmaceutical Preparations Pharmacologic Substance Phenocopy Phenotype Phosphatidylinositide 3-Kinase Inhibitor Phosphatidylinositol 4,5-Diphosphate Phosphotransferases Physiological Point Mutation Problem Solving Program Development Public Health Research Resistance Resolution Role Scientist Signal Pathway Signal Transduction Structure Study models System Testing Therapeutic Tissues Tumor Suppressor Proteins Virus Xenograft procedure base cancer cell cancer therapy cell growth chemical genetics drug candidate druggable target effective therapy experimental study glioma cell line human tissue in vivo inhibitor/antagonist inositol polyphosphate multikinase kinase inhibitor member mouse model mutant tool tumor

项目摘要

Abstract: The tumor suppressor PTEN counteracts Class 1 PI3-kinase functions in membranes, leading to the massive kinase inhibitor development efforts currently attempting to counteract loss of PTEN in human tumors. However, we discovered a new PTEN signaling pathway in the nucleus that is completely decoupled from Class 1 PI3-kinases. The “decoupling” is important for anti-cancer drug design because if a tumor is growing due to loss of nuclear PTEN, Class 1 PI3-kinase inhibitors would be ineffective against those tumors. Indeed, PI3-kinase inhibitors often fail to rescue loss of PTEN function in clinical trials, for incompletely understood reasons. Further, this new PTEN pathway has never been studied in any model of cancer, as we discovered it fortuitously while examining endocrine disorders. The kinase opposing PTEN in the nuclear pathway is a poorly characterized member of the inositol kinase superfamily called “Inositol Polyphosphate Multikinase” (IPMK). IPMK is a nuclear PIP2-kinase with ubiquitous expression in all human tissues, structurally unrelated to Class 1 PI3-kinases. Alfred Yung showed certain glioblastoma cell lines halted growth when complemented with nuclear, not cytoplasmic PTEN2. Based on the nuclear pathway, we hypothesized IPMK knockout might mimic nuclear PTEN complementation in these cells. Indeed, preliminary data show CRSIPR knockout of IPMK phenocopies nuclear PTEN complementation in these cells. Wild type but not kinase-dead IPMK rescues the phenotype, suggesting an IPMK inhibitor could be an effective therapy. This grant develops a chemical genetic mutant of IPMK to determine if IPMK inhibitors would be effective in glioblastoma. Future projects will use physiologically relevant mouse models to establish IPMK as a validated target for full scale industrial kinase inhibitor efforts.

文摘: